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A B S T R A C T
Purpose
Patients with gliomas often experience cognitive deficits, including problems with attention and
memory. This randomized, controlled trial evaluated the effects of a multifaceted cognitive
rehabilitation program (CRP) on cognitive functioning and selected quality-of-life domains in
patients with gliomas.
Patients and Methods
One hundred forty adult patients with low-grade and anaplastic gliomas, favorable prognostic
factors, and both subjective cognitive symptoms and objective cognitive deficits were recruited
from 11 hospitals in the Netherlands. Patients were randomly assigned to an intervention group or
to a waiting-list control group. The intervention incorporated both computer-based attention
retraining and compensatory skills training of attention, memory, and executive functioning.
Participants completed a battery of neuropsychological (NP) tests and self-report questionnaires
on cognitive functioning, fatigue, mental health–related quality of life, and community integration
at baseline, after completion of the CRP, and at 6-month follow-up.
Results
At the immediate post-treatment evaluation, statistically significant intervention effects were
observed for measures of subjective cognitive functioning and its perceived burden but not for the
objective NP outcomes or for any of the other self-report measures. At the 6-month follow-up, the
CRP group performed significantly better than the control group on NP tests of attention and
verbal memory and reported less mental fatigue. Group differences in other subjective outcomes
were not significant at 6 months.
Conclusion
The CRP has a salutary effect on short-term cognitive complaints and on longer-term cognitive
performance and mental fatigue. Additional research is needed to identify which elements of the
intervention are most effective.
J Clin Oncol 27. © 2009 by American Society of Clinical Oncology
INTRODUCTION
Gliomas, the most common type of primary brain
tumors, and their treatment can cause deficits in
various cognitive domains, including attention,
memory, and executive functioning.1-3 Although
these impairments, in general, are not severe in na-
ture,2,4,5 they can have a significant impact on pa-
tients’ daily lives.6 Moreover, subjective cognitive
symptoms are among the most common neurologic
problems reported by patients with brain tumors.7,8
Pharmacologic interventions have not proven
effective yet in the treatment of cognitive deficits in
patients with gliomas.9 Cognitive rehabilitation in-
terventions represent an alternative treatment ap-
proach. Only one small, retrospective study has
investigated cognitive rehabilitation in patients with
primary brain tumors.10 Although the results were
positive, they were not based on statistical testing.
Cognitive rehabilitation efforts have proven effec-
tive in other patient populations, including in those
patients with traumatic brain injury,11 stroke,11 and
Alzheimer’s disease.12
This randomized, controlled trial investigated
the effectiveness of a multifaceted cognitive rehabil-
itation program (CRP) on objective and subjective
measures of cognitive functioning in patients with
gliomas whose diseases were in remission. The pri-
mary hypothesis was that patients who underwent
the CRP would perform significantly better on ob-
jective neuropsychological (NP) tests of attention,
memory, and executive functioning and would
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report significantly fewer cognitive symptoms than patients in a
waiting-list control group. It was also hypothesized that the
CRP would have a significant, positive effect on self-reported
mental fatigue, mental health–related quality of life (QOL), and
community integration.
PATIENTS AND METHODS
Study Sample and Design
Eligible patients were identified via pathology databases or direct referral
from 11 Dutch hospitals, including 10 of the 18 Dutch neurosurgical centers.
Medical inclusion criteria were as follows: histologically proven or presumed
(on the basis of clinical and magnetic resonance imaging features), diffuse,
low-grade (ie, WHO grade 2) gliomas (ie, astrocytomas, oligodendrogliomas,
or oligoastrocytomas) and age between 18 and 70 years; or anaplastic gliomas,
age younger than 50 years, and good performance status (ie, Karnofsky per-
formance score  70). Patients had to be clinically stable (ie, without any
evidence of disease progression) for a minimum of 6 months before study
entry, and they could not be receiving antitumor treatment during that period.
Exclusion criteria included the following: any additional serious neurologic or
psychiatric disorder; inability to undergo the NP assessments (NPAs) or CRP
because of premorbid IQ score less than 85; visual, motor, language, or other
severe cognitive problems; lack of basic proficiency in Dutch; or participation
in a concurrent study with NP testing and/or health-related QOL assessments.
Patients with progressive disease during the course of the study were not
automatically excluded from additional participation; this decision was left up
to the individual patient.
Medically eligible patients were invited by their physicians to undergo
screening for cognitive eligibility (Fig 1). They were screened first via a tele-
phone interview for the presence of subjective cognitive symptoms. Those who
reported at least one cognitive symptom from the Medical Outcomes Study
(MOS) Cognitive Functioning Scale (CFS)13 (Table 1) and who indicated
interest in participating in a CRP were referred for objective NP testing.
Patients who scored at least one standard deviation less than the mean of a
healthy comparison group (N  294)35 on at least four of 20 objective NP test
variables were considered eligible. By employing both subjective and objective
cognitive eligibility criteria, it was possible to identify patients who would both
be motivated to participate and who would potentially benefit from the CRP.
Patients were assigned to the intervention group or to a waiting-list
control group by means of the minimization method,36 which balanced on
age, sex, education, tumor grade, hemisphere, radiotherapy, neurosurgery,
disease duration, and institution.
To evaluate the effect of the CRP, a battery of NP tests and self-report
questionnaires was administered at baseline, directly after cognitive rehabili-
tation (or an equivalent time point for the control group), and at the 6-month
follow-up. Participants were offered the choice of undergoing the NPAs and
the CRP sessions in their home or at their hospital. The trial was approved by
the institutional review boards of all participating hospitals, and all patients
provided written, informed consent.
 n = 66 
Attrition (n = 4)
  Progressive disease (n = 1)
  Medical problems (n = 1)
  Psychosocial problems (n = 2)
Intervention group (n = 70)
n = 69 
Attrition (n = 1)
 Lack of motivation (n = 1)












Excluded (n = 161)
 No cognitive complaints (n = 72)
 Cognitive complaints  
    but no burden (n = 21)
 No time (n = 18)
 Emotionally too 
    confronting  (n = 15)
 Serious visual/verbal/motor/ 
    cognitive handicap (n = 12)
 Other (neuro)psychological 
    therapy (n = 6)
 Inaccessible (n = 6)
 Other (n = 11)
Excluded (n = 65)
  No cognitive deficits (n = 39)
  Serious visual/verbal/motor/ 
    cognitive handicap (n = 13)
  Intervening medical 
    problems (n = 5)
  Lack of motivation (n = 4)
  Emotionally too 
    confronting  (n = 2)
  Psychiatric disorders (n = 2)
n = 64 
Lost to follow-up (n = 2)
  Progressive disease (n = 2)
n = 63 
Lost to follow-up (n = 6)
  Progressive disease (n = 3)
  Deceased (n = 2)
  Inaccessible (n = 1)
Second neuropsychological assessment (N = 135)
Third neuropsychological assessment (N = 127)
7-week CRP
Booster Empathy
Fig 1. Flow of participants through the
trial (enrollment and attrition). CRP, cogni-
tive rehabilitation program.
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Table 1. Objective and Subjective Outcome Measures
Test Name Subscore or Subtest Parameter Measured
Objective measures
Screening tests
DART (Dutch Adult Reading Test)14 Premorbid intelligence
DMT (Drie-Minuten-Toets) Three-Minute-Test15 Reading abilities
SCWT (Stroop Color-Word Test)16,17 Subtests: Card I, card II, card III, interference Attention, information processing speed, mental control
LDST (Letter Digit Substitution Test)18 Subtests: Writing, reading, motor Attention, information processing speed, psychomotor
speed
MST (Memory Scanning Test)19 Subscores: Slope, intercept Speed of memory processes
VVLT (Visual Verbal Learning Test), direct and
delayed recall20
Subscores: Trial 1, max, delta, total, delayed recall,
recognition
Verbal learning and memory
CST (Concept Shifting Test)21 Subtests: CST-A, CST-B, CST-C, CST-motor Attention, executive functioning, psychomotor speed
CF (Category Fluency) animals, from the GIT22 Subscore: Number correct Speed and flexibility of verbal thought process and
application of strategies
Neuropsychological tests for the evaluation of intervention effects
Attention
SCWT16,17 Subtest: Card III (time in seconds)‡ Attentional inhibition of a dominant response
DS (Digit Span) from the WAIS-R23 Forward (span: 0-8)† Immediate verbal recall
Backward (span: 0-7)† Working memory
LDST18 90 Sec writing (number correct: 0-125)† Psychomotor speed and speed of information
processing
MST19 Slope (time score)‡ Time needed for memory scanning
Intercept (time score)‡ Time to complete nonmemory stages
TEA (Test of Everyday Attention)24 El-Dis (Elevator counting with distraction; number
correct: 0-10)†
Auditory selective attention and working memory
Verbal memory
VVLT, direct and delayed recall20 Trial 1 (number correct: 0-15)† Immediate verbal span
Delta (number correct: 0-15)‡ Verbal learning effect
Delayed recall (number correct: 0-15)† Verbal memory after an interval
Executive functions
CST21 Subtest: CST-C (time in seconds)‡ Alternating attention
LF (Letter Fluency)25 Score: Number correct (0-)† Speed and flexibility of verbal thought process
CF animals and professions, from the GIT22 Score: Number correct (0-)† Speed and flexibility of verbal thought process and
application of strategies
BADS (Behavioural Assessment of the
Dysexecutive Syndrome)26,27
Subtest: Zoo map (profile score: 0-4)† Planning and priority setting
TEA (Test of Everyday Attention)24 El-Rev (Elevator counting with reversal; number
correct: 0-10)†
Auditory working memory
TelCount (Telephone search while counting;




CFS (Cognitive Functioning Scale) from the
MOS13
Total score (6-36)† Frequency of cognitive complaints
Burden (study-specific measure) Total (3-18)† of three questions on the impact of
cognitive complaints on daily life, worry about
cognitive complaints, being troubled by the
cognitive complaints
Burden of CFS complaints
CFQ (Cognitive Failure Questionnaire)28,29 Total score (0-100)‡ Cognitive failures in daily life
SF-36 (Short-Form 36) from the MOS30,31 Mental component summary score (Mean  50:
SD  10)†
Mental health–related quality of life
MFI (Multidimensional Fatigue Inventory)
32
Mental fatigue, reduced activity, reduced motivation
(4-20)‡
Mental aspects of fatigue




Motivation Study-specific measure administered for screening
purposes
Motivation to participate in the CRP
Evaluation Study-specific evaluation form administered after
completion of the CRP
Patients’ evaluation of the CRP
Screening tests used available normative data (from a sample of 294 individuals comparable to study sample based on age, sex and education.35
Neuropsychological tests were specifically selected for evaluation of possible intervention effects. Subjective measures were self-report questionnaires. Not all
screening variables were used as evaluation variables, as some of the screening measures were considered as less relevant for the evaluation of the intervention
effect and some other variables did not meet the assumptions for doubly multivariate repeated measures analyses of covariance. Not all tests for evaluation of
intervention effects were used as screening measures because of a lack of normative data.
Abbreviations: GIT; Groningen Intelligence Test; WAIS-R, Wechsler Adult Intelligence Scale-Revised; MOS, Medical Outcomes Study; CRP, cognitive rehabilitation program.
Klein.34
†Higher scores indicate better performance.
‡Higher scores indicate worse performance. Score or scale ranges are in parentheses;  indicates score has no upper limit.
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CRP
The CRP consisted of six weekly, individual sessions of 2 hours each. The
intervention, carried out by one of seven neuropsychologists, incorporated both
cognitive retraining and compensation training (Table 2). For the retraining com-
ponent,acomputerprogram(C-Car37)wasdeveloped,whichconsistedofaseries
of hierarchically graded tasks designed to strengthen various aspects of attention
on the basis of patient needs. The program focused on attention, because
attention deficits are frequently experienced by patients with gliomas,38,39 and
rehabilitation of attention deficits also may have a salutary effect on other
cognitive domains.40-43 The compensation training component consisted of
six psychoeducation sessions that addressed attention, memory, and executive
function. These sessions included both didactic and practical elements aimed
at helping patients compensate for impaired cognitive functions.
Additional weekly homework assignments consisted of computer-based
attention retraining exercises and of logs kept about experiences with applying
compensatory strategies in daily life. Approximately 3 months after comple-
tion of the CRP, participants had a telephone-based booster session, during
which key aspects of the compensation training were re-emphasized.
Control Condition
The waiting-list control group received usual care (ie, regular medical
follow-up; no cognitive interventions). Contact with the research staff was at
similar intervals as the intervention group, except for the CRP sessions.
Control-group patients also received a telephone-based empathy session, dur-
ing which attention was paid to possible cognitive problems but without
explicit advice as to how to deal with them. At completion of the study,
participants in the control group were offered the opportunity to undergo
the CRP.
Study Measures
Sociodemographic data, including age, sex, and education, were ob-
tained via personal interview. Clinical variables, including tumor characteris-
tics, treatment history, and antiepileptic drug use, were obtained from the
medical records.
An extensive battery of NP tests (Table 1) was administered to objectively
assess attention, verbal memory, and executive function. Also included were
two tests to identify patients with a premorbid IQ less than 85 and/or serious
reading problems.
Two self-report questionnaires (Table 1) were used to assess subjective
cognitive symptoms and functioning: the MOS CFS,13 supplemented by three
additional questions on perceived symptom burden (ie, burden) and two
questions on motivation to participate in the CRP; and the Cognitive Failure
Questionnaire (CFQ), which assessed cognitive problems in daily life.28,29
Other self-report measures included the three mental subscales of the
Multidimensional Fatigue Inventory (MFI),32 the mental component
summary score (MCS) of the Short-Form 36 (SF-36) Health Survey,30,31
and the three subscales of the Community Integration Questionnaire
(CIQ).33 After completion of the CRP, patients in the intervention group
were queried about their experiences with the program. The NP assessors
were blinded to group allocation.
Sample Size Calculations and Statistical Methods
With  set at .05, power at .80, and a minimal Cohen’s effect size for
between-group differences (d) in the primary outcomes of 0.50, a minimum of
64 patients per group was required.44 Independent t tests, 2 tests, and Mann-
Whitney tests were used to compare group baseline characteristics and to select
possible covariates. For the primary statistical analysis, a hierarchical approach
Table 2. Description of the Cognitive Rehabilitation Program
Overall description
Six weekly, individual sessions of approximately 2 hours, plus several hours of homework, provided by a neuropsychologist. Both compensatory strategies
(for attention, memory, and executive functioning) and (computer-based attention) retraining
Compensation training
Six integrated psychoeducational lessons addressing attention, memory, and executive function (“planning”), with both didactic and practical/experiential
elements. Text chapter was read in advance of the session, the content was discussed in that specific session, and homework was completed
afterward and discussed at the start of the next session
Session 1: Cognitive problems; methods of cognitive rehabilitation; compensation: factors influencing cognitive functioning (homework example: keeping a
daily log of cognitive problems encountered in daily life)
Session 2: The cognitive functions attention, memory and executive functioning and their interrelationships; compensation techniques: general conditions,
strategies and external devices to improve functioning; relaxation exercises (homework examples: finding strategies for cognitive problems noted in
daily log; finding personal situations for application of the general conditions, strategies and devices in daily life)
Session 3: Attention and its relevance; strategies for selective, sustained attention, alternating attention, and divided attention; psychological factors of
influence (homework example: matching strategies to personal situations, eg, for preventing external distraction)
Session 4: Planning and regulation; designing a plan; strategies for planning an activity; strategies for planning multiple activities (homework examples:
application of the ‘Seven-Steps-of-Planning-Scheme’, planning a busy day)
Session 5: Memory and its functioning; conditions, strategies and external devices (homework example: keeping a log of memory problems and the
application of memory strategies to them)
Session 6: Summary of the five former sessions: general overview of the compensation training, re-emphasis of specific conditions, strategies and
devices to improve functioning (no homework)
Retraining
For the retraining component, a computer program, ’C-Car’ (Concentration Car16), was developed by the research team in close collaboration with
NeuroCognitief Centrum Nederland
Training of four aspects of attention:
Sustained (prolongation of exercises)
Selective (addition of distraction)
Alternating (alternation between exercises)
Divided (performing multiple tasks simultaneously)
Attractive “game-like” platform (driving an old-timer car and processing information from road signs in changing landscapes)
Exercises in both the visual and the auditory modality; verbal and nonverbal exercises
Tailored to the needs of the individual patient by hierarchical grading of tasks: As soon as the patient has mastered preliminary attentional skills, higher
level skills are trained
Real-time feedback to the patient
Automatic registration of a number of outcome variables
Primarily consisting of homework: Exercising (“whenever, wherever”) by using a notebook computer
Gehring et al
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Table 3. Patient Demographics and Disease Characteristics
No. of Patients
Characteristic Intervention Group Control Group Intervention Group Control Group P
Available for evaluation 70 70
Age in years .303
Mean 42.0 43.8












Low grade (2) 58 59




















Years since last tumor treatment‡ .495
Median 2.6 3.1
Range 20.6 14.1






No. of test scores  1 SD below the norm group mean .732
Mean 7 7
SD 13 15
Progressive disease at NPA2 (N  135)† .178
No 59 56
Yes 7 13
Progressive disease at NPA3 (N  127)†§ .007
No 57 44
Yes 7 19
The following factors were used for stratification in minimization: patient age, sex, and education; disease duration; tumor grade; hemisphere; surgery; cranial
irradiation; and institution (not shown).




§Total number of patients in the intervention group with progressive disease at NPA3  7 (7 with PD at NPA2  2 who subsequently discontinued study
participation (see Fig 1)  2 diagnosed with PD between NPA2 and NPA3). Total number of patients in the control group with progressive disease at NPA3  19
(13 with PD at NPA2-3 who subsequently discontinued study participation (Fig 1)  9 diagnosed with PD between NPA2 and NPA3).
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was used to minimize the possibility of type I errors as a result of multiple
testing. First (ie, step 1), six doubly multivariate, repeated-measures analyses of
covariance (ANCOVAs)45 were conducted on conceptually related objective
and subjective measures to investigate group differences over time. The NP
tests were clustered into attention, memory, and executive functioning do-
mains (Table 1). The CFS, burden questionnaire, and CFQ were analyzed
together, as were the three MFI subscales and the three CIQ subscales. The
SF-36 MCS was analyzed separately by using repeated measures ANCOVA.
In step 2, those sets of outcomes that yielded statistically significant
between-group differences on the basis of the doubly multivariate, repeated-
measures ANCOVAs were submitted to additional statistical testing using
multivariate analyses of covariance (MANCOVAs) to determine if observed
group differences were present at immediate postintervention and/or at the
6-month follow-up.
In step 3, in those grouped variables for which the simple MANCOVAs
yielded significant results at immediate postintervention and/or at 6-month
follow-up, a series of ANCOVAs was carried out separately for the individual
outcome measures.
In all analyses, relevant baseline values (eg, baseline memory scores when
memory test variables were the dependent variables) and possible confounders
(eg, disease progression) were included as covariates. The magnitude of statis-
tically significant group differences as analyzed by the ANCOVAs was calcu-
lated according to the formula for generalized eta-squared46 and was
converted to Cohen’s d statistic.44 According to Cohen’s guidelines,44 an effect
size of 0.20 was considered small, 0.50 was medium, and 0.80 was large.
Additionally, group differences in the proportion of patients that no
longer met our criteria for cognitive impairment at both follow-up assess-
ments were analyzed with 2 tests. Finally, a subgroup analysis was performed,
which excluded patients who experienced disease progression during the
course of the study, and a sensitivity analysis was carried out to determine
whether the timing of disease progression had an effect on immediate or
long-term outcomes.
For all statistical tests, SPSS 15.0.1 (SPSS Inc, Chicago, IL) was used, and
P less than .05 was considered statistically significant.
RESULTS
Patient Recruitment
Patients were enrolled from November 2004 until December
2006. After various levels of screening (Fig 1), 140 eligible patients were
randomly assigned to the intervention group or to the waiting-list
control group. During the course of the study, 13 patients (six in the
intervention group; seven in the control group) were lost to follow-up,
primarily as a result of progressive disease.
Table 4. Immediate and Longer Term Effects of Cognitive Rehabilitation on Neuropsychological Measures in Patients With Gliomas
NPA1 N  140 NPA2 N  135 Immediate Effects NPA3 N  127
Longer Term
Effects
Intervention Group Control Group
Intervention




Group Control Group P
Effect
Size
dOutcome Measure Mean SD
Z
 1 Mean SD
Z













Step 2 .463 .004
SCWT card III 110.94 41.28 44% 119.97 53.92 54% 103.93 37.40 103.29 31.20 — 103.16 32.61 110.62 27.20 .041 0.23
DS
Forward 5.23 1.08  5.14 0.98  5.52 1.46 5.52 1.21 — 5.53 1.19 5.17 0.99 .004 0.43
Backward 4.49 1.09  4.29 0.95  4.64 1.36 4.30 1.13 — 4.74 1.23 4.18 1.02 .001 0.55
LDST 90 sec
writing 43.23 8.74 66% 42.19 9.04 64% 48.49 7.66 47.05 6.39 — 49.38 8.02 47.12 6.69 .010 0.26
MST
Slope 16.05 10.49 24% 14.67 7.54 24% 13.61 6.73 13.86 5.61 — 13.82 7.33 15.72 6.12 .095
Intercept 28.83 8.43 53% 30.67 9.75 54% 27.76 9.25 27.91 7.72 — 28.09 8.24 28.15 6.87 .692
TEA El-Dis 7.32 2.75  7.26 2.69  8.33 2.39 8.08 1.99 — 8.32 2.67 7.79 2.23 .078
Verbal memory
Step 1 .015
Step 2 .323 — .009
VVLT
Trial 1 5.77 2.29 13% 5.61 1.66 11% 7.68 2.55 7.46 2.10 — 8.82 2.78 7.86 2.29 .003 0.48
Delayed recall 9.17 3.19 27% 8.94 2.95 34% 11.34 3.14 10.87 2.58 — 12.08 3.32 10.79 2.74 .002 0.43




CST-C 37.13 15.50 34% 39.41 17.30 41% 30.52 17.17 33.22 13.52 — 35.91 19.83 35.63 16.26 —
LF 19.41 8.37  18.91 8.51  21.29 7.29 21.69 5.98 — 20.59 8.87 20.77 7.27 —
CF 35.79 7.86 43% 37.31 9.41 33% 37.88 9.48 37.56 7.78 — 38.61 8.55 36.12 7.01 —
BADS Zoo map 2.21 1.24  2.17 1.30  2.46 1.57 2.34 1.29 — 2.76 1.57 2.46 1.29 —
TEA El-Rev 4.64 3.01  3.74 2.78  5.68 3.10 5.78 2.54 — 6.34 3.28 5.35 2.70 —
TEA TelCount 1.87 2.76  3.79 7.79  1.52 3.28 1.40 2.69 — 1.19 2.49 1.30 2.04 —
For first neuropsychological assessment (NPA1), raw unadjusted means are shown; for NPA2 and NPA3, means are corrected for covariates. Dashes indicate that
models at steps 2 and 3 were not performed because of a statistically nonsignificant result in the prior step.
Abbreviations: Z  1, percentage of patients out of 70 with score of at least 1 SD below the norm group mean; SD, standard deviation; SCWT, Stroop Color-Word
Test; DS, Digit Span; LDST, Letter Digit Substitution Test; MST, Memory Scanning Test; TEA, Test of Everyday Attention; El-Dis, Elevator Counting with Distraction;
VVLT, Visual Verbal Learning Test; CST, Concept Shifting Test; LF, Letter Fluency; CF, Category Fluency; BADS, Behavioural Assessment of the Dysexecutive
Syndrome; El-Rev, Elevator Counting With Reversal; TelCount, Telephone Search While Counting.
No norm group data available.
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Sociodemographic and Clinical Characteristics
No statistically significant differences were observed between
groups in sociodemographic or baseline clinical characteristics
(Table 3). However, at the third assessment, the incidence of pro-
gressive disease was significantly higher in the control group (Table
3). As disease progression at this third assessment was related
significantly to two of the outcomes (MFI reduced motivation
[P  .030] and CIQ total score [P  .008], we employed it as a
time-varying covariate in all step-1 analyses. For steps 2 and 3, we
employed progression at the second NPA (NPA2) as a covariate for
the short-term interval (NPA2  NPA1) analyses, and progression
at the third NPA (NPA3) for the long-term interval (NPA3 
NPA1) analyses.
Baseline NP and Subjective Measures
There were no statistically significant between-group differences
in baseline NP test scores (Table 4). However, the intervention group
scored significantly worse at baseline on the MFI scales and on the
SF-36 MCS (Table 5). As stated in the Patients and Methods section,
all baseline scores on the NP tests and subjective measures that were
Table 5. Immediate and Longer Term Effects of Cognitive Rehabilitation on Subjective Measures in Patients With Gliomas
Immediate Effects Longer Term Effects




















Step 2 .001 .311
CFS total .000 0.48 —
Mean 21.01 22.07 25.75 23.34 24.44 23.78
SD 4.24 4.63 4.50 3.77 6.21 5.20
Burden total .009 0.38 —
Mean 9.81 10.76 11.98 10.68 11.96 11.47
SD 2.85 3.15 3.49 2.93 4.21 3.52
CFQ total .014 0.31 —
Mean 47.99 45.99 38.33 43.60 37.58 41.32
SD 10.31 14.22 12.56 10.52 14.07 11.78
SF-36 step 1 .165 —
MCS — —
Mean 42.03 46.35 46.94 44.21 45.14 43.63
SD 10.34 9.72 10.68 9.15 12.37 10.60
MFI
Step 1 .049
Step 2 .370 .044
Mental fatigue .026 0.41
Mean 15.33* 13.87 11.51 11.44 11.04 11.73
SD 3.09 4.02 2.42 1.97 2.55 2.08
Reduced activity .816
Mean 12.93 10.57 12.73 12.18 12.20 12.11




Mean 10.94 9.18 11.70 11.88 11.41 12.07
SD 3.74 3.67 3.02 2.46 2.65 2.16
CIQ step 1 0.980 — —
Home integration — —
Mean 5.79 5.85 5.97 6.02 5.68 5.75
SD 2.75 2.77 1.82 1.51 2.05 1.70
Social integration — —
Mean 8.63 8.63 9.05 8.78 8.65 8.43
SD 2.42 2.17 2.02 1.68 2.43 2.01
Productivity — —
Mean 4.03 4.00 4.23 4.21 3.70 3.71
SD 1.83 1.90 1.25 1.04 1.63 1.35
For first neuropsychological assessment (NPA1), raw unadjusted means are shown; for NPA2 and NPA3, means are corrected for covariates. Dashes indicate that
models at steps 2 and 3 were not performed because of a statistically nonsignificant result in the prior step.
Abbreviations: NPA, neuropsychological assessment; CFS, Cognitive Functioning Scale; SD, standard deviation; CFQ, Cognitive Failure Questionnaire; SF-36,
Medical Outcomes Study Short-Form 36; Mental CS, Mental Component Summary of the Mental Outcomes Study SF-36; MFI, Multidimensional Fatigue Inventory;
CIQ, Community Integration Questionnaire.
Statistically significant group difference at baseline   .05.
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directly related to the dependent variables were also included as co-
variates in the analyses.
Overall Effects
Significant group differences over time were observed for
objective NP measures of attention (P  .028) and verbal memory
(P  .015; Table 4; Fig 2). Differences in measures of executive
functioning were not statistically significant.
For the subjective measures (Table 5; Fig 2), a significant
group difference over time was found for the combined analysis of
the CFS total score, burden, and CFQ total score (P  .003) and for
mental aspects of fatigue (P  .049). There were no statistically
significant group differences over time for the remaining self-
report measures.
As these initial analyses had a gatekeeper function, additional
statistical testing was carried out only for test scores of attention and
verbal memory (Table 4) and for the self-reported measures of cogni-
tive functioning and mental fatigue (Table 5).
Short-Term NP Outcomes
Immediately post-treatment, there were no statistically signifi-
cant group differences in attention or verbal memory scores. Both
study arms showed similar improvement in most of the attention and
memory tests (Fig 2), and the percentage of patients that no longer met
criteria for cognitive impairment did not differ between groups (28% v
30% in the intervention and control group, respectively; P  .801).
Long-Term NP Outcomes
At the 6-month follow-up, a statistically significant group
difference was found for the combined attention tests (P  .004).












































































































































Fig 2. Corrected means and standard errors (bars) of significant objective and subjective intervention effects (N  127). SCWT, Stroop Color-Word Test; DS, Digit
Span; LDST, Letter-Digit Substitution Test; VVLT, Visual Verbal Learning Test; CFS, Cognitive Functioning Scale; CFQ, Cognitive Failure Questionnaire; MFI,
Multidimensional Fatigue Inventory. (*)Higher scores indicate better performance. (†)Higher scores indicate worse performance.
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group differences that favored the CRP group, and effect sizes
ranged from 0.23 to 0.55.
Similarly, significant group differences were observed for the
combined tests of verbal memory (P  .009), and two of the three
individual variables yielded significant results that favored the CRP
group (effect sizes, 0.48 and 0.43).
The percentage of patients who no longer met criteria for cogni-
tive impairment at the 6-month assessment was 39% in the interven-
tion group versus 21% in the control group (P  .027).
Short-Term Subjective Outcomes
Immediately post-treatment, statistically significant differences
that favored the intervention group were found in self-reported cog-
nitive functioning (CFS, burden, and CFQ; P  .001), and effect sizes
ranged from 0.31 to 0.48. There were no significant, short-term group
differences in mental fatigue scores.
Long-Term Subjective Outcomes
At the 6-month follow-up, there were no longer statistically sig-
nificant group differences in self-reported cognitive functioning. The
pattern of results (Fig 2) suggests that the CRP group largely main-
tained its gains in self-reported cognitive functioning, whereas the
control group exhibited continued gains over time. Statistically signif-
icant group differences that favored the intervention group were ob-
served for the MFI scales (P  .044), in particular for mental fatigue
(effect size, 0.41).
Subgroup and Sensitivity Analyses
As the number of patients whose disease progressed during the
study differed between the groups, a subgroup analysis was performed
in which patients with progressive disease (n26) were excluded. The
results indicated significant intervention effects for verbal memory
(P  .048) and subjective cognitive functioning (P  .008). Group
differences in attention and mental fatigue were no longer statisti-
cally significant. However, it should be noted that these analyses
had substantially less statistical power because of the reduced sam-
ple size (n  101 v n  127 in the primary analysis).
A sensitivity analysis was performed (N  127), in which it was
assumed that progression occurred either at NPA2 or at NPA3. The P
values for these (ie, step 2) MANCOVAs per domain were all in the
same range (data not shown). This indicated that the timing of disease
progression did not affect immediate or long-term outcomes.
Patient Evaluations of CRP
Eighty percent of the patients in the CRP group reported that the
content of the program largely/completely addressed their cognitive
problems, 87% used the learned compensation strategies regularly/
often in daily life, and 79% indicated a decrease in the impact of
cognitive problems on daily functioning.
DISCUSSION
In this trial we observed significant improvement in self-reported
cognitive functioning at the immediate postintervention assessment,
but not at the 6-month follow-up. Conversely, although no significant
group differences in NP test scores were observed at the immediate
postintervention, clear differences in attention and verbal memory
were found at the 6-month follow-up. The magnitude of the observed
effects was moderate. Consistent with these results, the percentage of
patients who no longer met criteria for cognitive impairment was
similar for both groups at the immediate post-treatment, but the
percentage was significantly higher in the CRP group at the
6-month follow-up. Significant intervention effects were also
found for long-term mental fatigue scores. The CRP did not have a
significant effect on self-reported mental health–related QOL or
community integration.
The absence of a significant group effect for the objective NP
measures immediately after the intervention may reflect the fact that
both study arms exhibited improved objective cognitive performance
(ie, attention and memory) in the short term. A practice effect (ie,
improved test performance as a result of repeated NP test comple-
tion), or regression to the mean, may have initially overwhelmed any
intervention effect. At the 6-month assessment, the CRP group exhib-
ited continued improvement in objective cognitive performance,
whereas the control group did not. This delayed salutary intervention
effect on cognitive performance may indicate that patients require a
longer period of time to integrate learned strategies into their
daily routine.47-49
The positive effects observed on mental fatigue may reflect a
direct effect of the intervention (ie, learned time management
strategies) or an indirect effect that results from improved cogni-
tive functioning.
The fact that significant group differences were observed in self-
reported cognitive functioning in the short term but not in the long
term should be interpreted in light of the pattern of change over time.
The CRP group reported a significant improvement in self-reported
cognitive functioning early on, and this was largely maintained
through to the 6-month follow-up. The control group exhibited a
smaller, more gradual improvement in self-reported cognitive
functioning over time, which might reflect a combination of regres-
sion to the mean,50 response shift,51 and natural recovery (eg,52,53).
The discrepancy observed between objective and subjective cog-
nitive measures is consistent with results of earlier studies among
patients with cancer and with other neurologic disorders.54,55 In gen-
eral, self-reported cognitive functioning tends to correlate more highly
with self-reported measures of distress and with well-being than with
objective NP tests.56-58
Several possible limitations of the study should be noted. First,
the study included a relatively large number of outcome measures.
This was necessary, given the complex nature of the phenomena under
investigation and the current state-of-the-art of NPA. To minimize
the possibility of type I errors, we employed a hierarchical approach to
the statistical analysis.
Second, the study results can only be generalized to glioma pa-
tients who both report having cognitive symptoms and score below a
predetermined cutoff on objective NP tests. They may not apply to
patients who have significant cognitive impairment on the basis of
objective test results, but who do not report cognitive symptoms. Also,
the results may apply only to patients with relatively mild deficits,
similar to the group studied, who have sufficient cognitive resources
and motivation to follow the rehabilitation program. Finally, the study
could not tease out the relative effectiveness of cognitive retraining
versus the use of compensatory strategies.
In conclusion, this first, randomized, controlled trial of cognitive
rehabilitation in patients with gliomas provides initial evidence of a
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salutary effect on short-term cognitive complaints and on longer-term
cognitive performance and mental fatigue. Future trials are needed to
more clearly identify the most effective elements in such a program, to
determine how to achieve a sustained, positive effect on cognitive
problems in daily life, and to determine the value of such a CRP when
used with other patient populations with NP deficits.
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